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The Na+/K+-ATPase is a membrane ion-transporter protein, specifically inhibited by digi-
talis glycosides used in cardiac therapy. The existence in mammals of some endogenous
digitalis-like factors (EDLFs) as presumed ATPase ligands is generally accepted. But the
chemical structure of these factors remained elusive because no weighable amounts of
pure EDLFs have been isolated. Recent high-resolution crystal structure data of Na+/K+-
ATPase have located the hydrophobic binding pocket of the steroid glycoside ouabain. It
remained uncertain if the EDLF are targeting this steroid-receptor or another specific bind-
ing site(s). Our recently disclosed spherical oligo-silicic acids (SOSA) fulfill the main criteria
to be identified with the presumed EDL factors. SOSA was found as a very potent inhibitor
of the Na+/K+-ATPase, Ca2+-ATPase, H+/K+-ATPase, and of K-dp-ATPase, with IC50 val-
ues between 0.2 and 0.5µg/mL. These findings are even more astonishing while so far,
neither monosilicic acid nor its poly-condensed forms have been remarked biologically
active. With the diameter φ between 1 and 3 nm, SOSA still belong to molecular species
definitely smaller than silica nano-particles with φ>5 nm. In SOSA molecules, almost all
Si-OH bonds are displayed on the external shell, which facilitates the binding to hydrophilic
ATPase domains. SOSA is stable for long term in solution but is sensitive to freeze-drying,
which could explain the failure of countless attempts to isolate pure EDLF.There is a strong
resemblance between SOSA and vanadates, the previously known general inhibitors of P-
type ATPases. SOSA may be generated endogenously by spherical oligomerization of the
ubiquitously present monosilicic acid in animal fluids. The structure of SOSA is sensitive
to the concentration of Na+, K+, Ca2+, Mg2+, and other ions suggesting a presumably
archaic mechanism for the regulation of the ATPase pumps.
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INTRODUCTION
Investigating the staircase effect on frog ventricular muscle, it was
revealed in the early 1950s that human serum contains a factor,
which improves the contractile power of the heart, similar to plant-
derived digitalis glycosides (1). Besides the serum, this digitalis-like
activity was reproduced by a total extract of adrenal but, individ-
ual cortisol steroids were, with one exception, inactive. Referring
to their finding Szent-Györgyi concluded (2) in more general
terms that “such digitalis-like factors are ubiquitously distributed
in mammals” and “digitalis glycosides from plants are actually not
drugs but only substitutes of the body’s own digitalis-like factors.”
This kind of relationship between exogenous drug-substances,
which fits accidentally into the receptor of a body’s own factor
has been verified by the discovery of endorphins, the endoge-
nous counterparts of the plant-derived morphine (3). Why this
broadly accepted rationale was not consequently applied in the
differentiation between endogenous digitalis-like factors (EDLFs)
and exogenous digitalis glycosides is a subject of the present review.
A further milestone finding of the 1950s was that digitalis
glycosides inhibit the transport of Na+ and K+ ions across the
erythrocyte membrane (4) and above all the seminal discovery of
the membrane transport protein of the Na+ and K+-ions by Skou
(5). This Na+/K+-ATPase (adenosine-triphosphatase) abbrevi-
ated NKA or sodium pump is present in the membrane of all
eukaryotic cells. Every pumping cycle of the NKA moves 3 Na+
ions outward and 2 K+ ions inward, powered by the energy of a
phosphate bond from ATP.
At the beginning of the 1960s, the existence of a circulating
natriuretic factor was postulated by De Wardener et al. (6) show-
ing that the blood, transfused from a saline-loaded, hypertensive
dog, produces natriuresis in the recipient normotensive animal. It
was further observed that the plasma ultra-filtrate of saline-loaded
dogs inhibits the sodium transport in toad bladder and the vol-
ume expansion was accompanied by increasing concentrations of a
sodium pump-inhibitory factor (7). Ascertaining that both effects
were caused by the same factor the name natriuretic hormone
was proposed. The natriuretic fraction extracted from the plasma
of volume-expanded dogs inhibited the ouabain-insensitive NKA
from rat kidney (8).
After the identity of the natriuretic hormone with the sodium
pump-inhibitory factor was confirmed, the name EDLF came into
use (9). The initial idea that EDLF could be a natriuretic peptide
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was rejected after disclosure of the atrial natriuretic peptide (ANP),
which has, contrary to EDLF no NKA-inhibitory activity (10).
Though the structure of EDLF remained obscure, some of its
particular characteristics were established as for instance: its non-
peptide nature or its specific interaction with different ATPase iso-
forms. But the failure of all attempts to obtain weighable amounts
of pure EDLF impeded for more than five decades the disclosure
of its chemical structure.
Na+/K+-ATPase controls a broad spectrum of essential cel-
lular functions such as ion homeostasis, membrane potential,
pH, temperature, and water osmosis, thereby regulating impor-
tant physiological processes, e.g., muscle contraction, nervous
signal transmission, renal sodium retention, and vascular tone.
Study data in animal models and clinical observations in human
beings suggest that cardiac insufficiency, essential hypertension,
and other diseases may be caused by or connected to malfunction
or dysregulation of the sodium pump.
The extensive research work related to the structure, characteri-
zation, mechanism of action, and physiological implications of the
Na+/K+-ATPase was comprehensively reviewed by Gadsby et al.
(11), Glynn (12), Kaplan (13), and Jørgensen et al. (14). Similarly,
extensive reviews on the whole P-type-ATPase field have been pub-
lished by Møller et al. (15), Kühlbrandt (16) and by the original
contributions of Axelsen and Palmgren (17, 18) with special focus
on evolutionary aspects of the P-type ATPases.
ATPase RECEPTOR SITE
P-type ATPase is the generic designation of several ATP-driven
transmembrane ion pumps found in bacteria, archaea, and
eukaryotes. The prefix P refers to the ability of these proteins for
phosphorylation and de-phosphorylation of their catalytic aspar-
tate residue (15). By the binding and removal of the phosphate
group, ATPases interconvert between two conformations, denoted
by E1 and E2, each with different affinity to the nucleotide ATP
(adenosine triphosphate) and the transported ions (16). A com-
mon feature of P-type ATPases is their inhibition by vanadate ions
at micro- and sub-micro-molar concentrations.
From about 200 members of the P-type ATPase family, the most
prominent pumps are the cell membrane Na+/K+-ATPase (NKA);
the Ca2+-ATPase (SERCA) from sarcoplasmic reticulum (SR), the
gastric H+/K+-ATPase, and the bacterial K-dp-ATPase. Based on
80–90% similarities of the amino acid (AA) sequences in the con-
served regions, it is assumed that P-type ATPases evolved from a
common ancestor, probably 3500 million years ago (17, 18).
A seminal breakthrough for the detailed structural understand-
ing of the transmembrane ion pumping was achieved by the
first high-resolution (2.6Å) crystal structure of the SERCA Ca2+-
ATPase protein from SR solved by Toyoshima et al. (19). This
study established the detailed 3D structure and accomplished the
functional characterization of the cytoplasmic subunits designated
P (phosphorylation), N (nucleotide binding), and A (actuator)
domains. It was found that the ion-binding sites are surrounded
by the M4–M6 and M8 transmembrane helices where M4 and M6
provide the efficient geometry for the coordination of the Ca2+
ions. The over 50 Å distance between the membrane site of the
Ca2+ion translocation and the cytoplasmic phosphorylation site
is remarkably long.
In the next high-resolution (3.1 Å) crystal structure of the
SERCA pump, the Toyoshima group applied the sesquiterpene
lactone thapsigargin, to stabilize the Ca-free E2-(TG) state (20).
The comparison of both crystallized forms Ca2+E1 and E2-(TG)
revealed further details of the ion transport mechanism. In a fol-
lowing contribution (21), the structure of the Ca2+-ATPase was
solved in the E1 state fixed by the ATP-analog AMPPCP. In the
same year, the structure at 2.3 Å resolution of SERCA with phos-
phate analogs such as [MgF4]2- has been resolved (22). The studies
of the Ca-pump fixed with ATP- or phosphate analogs have com-
pleted the structural insight into almost all important states of the
pump turnover.
Resolving the crystal structure of the SERCA pump with the
phosphate mimic [BeF3]-, Olesen et al. (23) provided support
for the presence of an open ion pathway in the pump in which
the transmembrane domains form a funnel-shaped geometry.
As described later, the crystal structure data confirmed that P-
type ATPases share the same architecture regardless of the size,
charge, and number of ions that they transport. It seems that the
differences are largely confined to the ion-binding pocket (23, 24).
Na+/K+-ATPase is sensitive to inhibition by digitalis glyco-
sides (e.g., digoxin, ouabain), isolated from medicinal plants used
over centuries to treat congestive heart failure. The term “digitalis”
designates the entire group of cardiac glycosides and aglycones
without regard of their structure and origin (25). Responsible
for the cardiac activity is the aglycone, i.e., the steroid nucleus,
which results after the sugar moiety from position 3 is removed.
Steroid aglycones with five-membered lactone ring in position
17 are named cardenolides while those with six-membered lac-
tone ring bufadienolides. Both terms, cardiotonic (CTS) or cardiac
steroids (CSs), are in use but the adjective “tonic” is less rigorous
as it refers to a species-dependent physiological response; thus, the
designation CS should be preferred over CTS.
Since Na+/K+-ATPase is the target of digitalis drugs in heart
failure patients, it was of prior importance to establish structure–
activity relationships. A general correlation between binding
affinity and NKA-inhibitory potency of cardiac glycosides was
revealed (26) but some notable exceptions were also identified.
By replacement of the five-membered lactone ring in carde-
nolides with the 2-pyrone ring of bufadienolides, the binding
affinity declines but the inhibitory potency increased. Further-
more, while the removal of ouabain’s rhamnose moiety had little
effect on inhibitory potency, it caused a decline in ligand binding
affinity.
In a recent study, 30 different cardiac glycosides were investi-
gated for their interaction with the α1, α2, and α3 isoforms of the
human NKA expressed in Pichia pastoris (27). The study revealed
significant isoform selectivity by digoxin glycosides but ouabain
was found moderately α2 selective. The observed influence of the
sugar moiety on the selectivity was surprising since according to
pharmacological data this part influences rather the bioavailability
and metabolism of the digitalis drugs.
Biophysical methods provided further insight into the charge
transfer processes during the pump cycle. The binding of ouabain
is associated with movement of electrical charges; thus, it can be
followed by the charge-sensitive fluorescence indicator RH421.
These data revealed that the binding of ouabain or generally of
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a cardiac glycoside to the Na+/K+-ATPase protein will stabilize
under physiological conditions the E2P·2Na+ stage (28).
Na+/K+-ATPase is expressed in all animal cells and shows
highly conserved AA sequences in the main α subunit (~1000
AA residues) responsible for the catalytic function, similar to
that found in SERCA. This catalytic subunit of NKA has 10
transmembrane TM helices numbered M1–M10 from the amino-
terminal. Experiments with punctual mutations of AA residues
evidenced CS binding sequences in the extracellular loops L1/2,
L5/6, and L7/L8. The cytosolic loop L2/3 contains the nucleotide
(ATP) binding N site and the phosphorylation site P, while
the NH2 terminal and the L2/3 loop are responsible for the
de-phosphorylation step. NKA contains further the heavily gly-
cosylated ß-subunit with ca. ~300 AA and the tissue specific
auxiliary γ subunits FXYD of ca. 70–180 residues The multiple
regulatory potential of the NKA is explained by the existence
of tissue-specific assemblies of different structural subunits or
isoforms (29).
In comparison with more than 20 X-ray structures for Ca2+-
ATPase, for NKA only 5 crystal structures at better than 5 Å
resolution have been published. Some difficulties come from the
source of NKA protein, which is limited to rabbit kidney and
shark rectal gland, expressing selectively the α1 isoform. The
lack of very high-affinity inhibitors able to fix the enzyme in
one particular conformation posed further limitations to NKA
crystallization (29).
The crystal structure of the pig-renal Na+/K+-ATPase with 2
Rubidium ions as K ion congeners was solved at 3.6 Å resolution
by the PUMPKIN group in Denmark (30). The structure shows
that the conformation of the: α unit (in Rb/K occlusion) closely
matches the conformation of the Ca2+ ion bound state of SERCA.
The crystal structure of the Na+/K+-ATPase from shark
enzyme was resolved (31) at 2.4 Å resolution in the: E2·2K~Pi
state in which the pump has a high affinity to K+ ions. The coor-
dination of K+ ions in the transmembrane sites and the critical
role of the β subunit in binding of the K+ ions were remarked.
Despite identical coordinating residues, small differences with the
Ca2+-ATPase pump were noted.
Solving with 2.8 Å resolution, the crystal structure of Na+/K+-
ATPase, co-crystallized with ouabain in the E2·2K+~Pi state, the
authors concluded (32) that ouabain is deeply inserted into the
transmembrane domain, with lactone ring near to the K+ binding
site with partial unwinding of the M4E helix (see Figure 1A below).
This unwinding should explain why ouabain binding is so slow.
The data suggest reconsideration of previous data that CSs bind to
the extracellular surface of the ATPase α-subunit. Since ouabain
interacts with transmembrane segments M3, M4, and M6 involved
in ion transport this steroid can influence or block these processes.
Based on the crystal structure at 4.6 Å resolution of the pig
kidney Na+/K+-ATPase with ouabain bound in the E2P state,
it was suggested that the high-affinity binding of ouabain sta-
bilizes the phosphorylated state (33). The steroid binds to a site
formed betweenαM1 andαM6 domains, plugging the ion pathway
from the extracellular side. A high-affinity interaction is formed
between the steroid and the αM1–2 part from domain α, which is
rotated following the phosphorylation. Solving the crystal struc-
ture at 3.4 Å resolution of the phosphorylated pig kidney NKA
in complex with ouabain has revealed that the steroid binds with
intensive hydrogen bonding network to the αM1, αM2, and αM6
transmembrane segments (34). It was concluded that the binding
pocket in the [Mg2+] E2P state allows deep ouabain binding with
possible long-range interactions with Mg2+ and K+ ions.
FIGURE 1 | (A) Binding of ouabain to the hydrophobic site in NKA (32). (B) Binding of SOSA to the hydrophilic receptor site of decavanadate in SERCA (19).
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Applying fluorescein-labeled ouabain and a lanthanide binding
tag in the NKA derived from Xenopus oocytes the data of spectro-
scopic measurements (35) suggested two different type binding
sites for ouabain: one external, low-affinity site on the extracel-
lular end of the ion pathway as previously assumed; the second
high-affinity site is slightly deeper toward the intracellular end of
the ion pathway, as indicated by recent X-ray diffraction studies.
In conclusion, the high-resolution crystal structure data have
identified the location of ouabain in the NKA together with the
protein domains involved in the interaction with this CS. The
ouabain-binding site described in Ref. (32) has a flat hydrophobic
surface suitable for the interaction with the steroid frame as shown
by Figure 1A.
For some hydrophilic ATPase ligands such as the decavana-
date or the here disclosed spherical oligo-silicic acid (SOSA) (see
below), it is improbable to target the hydrophobic receptor site
of CSs and thus to compete directly with ouabain or digoxin. A
more suitable target for hydrophilic inhibitors in P-type ATPases
is the phosphorylation site in the cytoplasmic region between the
N, A, and P domains (Figure 1B), as it was suggested for the
decavanadate ion in SERCA (19).
The high-structural analogy between the hydrophilic poly-
anionic decavanadate and the here disclosed SOSA suggests that
SOSA should target ATPase pumps at the phosphorylation site in
a similar manner as decavanadate. This assumption is illustrated
by Figure 1B) with the high-resolution structure of the cytoplas-
mic domain of SERCA with the decavanadate ion bound to the
hydrophilic phosphorylation site (19).
DILEMMA: EDLF OR CARDIAC STEROIDS
The physiological role of the CS receptors and the existence of
endogenous non-steroidal ligands of NKA have been investigated
by the group of Lingrel (36, 37). The experiments were conducted
among others on some ouabain-resistant and ouabain-sensitive
isoforms (cc2, cc3, and cc4) genetically engineered in mice and
rat. The biological function and significance of the CS binding
site was evidenced with rigorous distinction between cardiotonic
steroids (CTS) and the yet undisclosed endogenous ATPase lig-
ands. Reviewing the whole set of his experimental results and their
significance for the physiological role of the NKA receptors, Lin-
grel concluded three main points: (1) the ouabain-binding site of
the Na/K-ATPase plays a physiological role, (2) an endogenous
ligand for the Na+/K+-ATPase must exist, and finally, (3) whether
the endogenous ligand acts through a change in intracellular Na+
or through a signaling mechanism is unknown (37).
Despite the convincing arguments of Lingrel, the relation
between EDL factors and CSs remained a dilemma, i.e., “a prob-
lem offering two possibilities, neither of which is acceptable.” In
fact, there are some experimentally identified but physically not
isolated (probably labile) EDL factors assumed as ATPase ligands
that differ markedly from CSs except for the inhibition of the NKA.
Lacking weighable amounts of EDL factors, the studies have been
performed only with the commercially available CSs and, there-
fore, could neither demonstrate nor exclude the identity of EDLF
with CS.
This unsolved dilemma has marked the extensive research work
focused to disclose the structure and properties of the putative
endogenous ligands of the ATPases as thoroughly reviewed by
Goto et al. (38), Hollenberg and Graves (39), Buckalew (40),
Schoner and Scheiner-Bobis (41), Nesher et al. (42), and Bagrov
et al. (43).
Numerous attempts to isolate pure EDL factors from various
biological sources (organs, glands, plasma, or urine) were listed by
these surveys (38–42). Despite applying extraction procedures on
several kilogram amounts of starting material and efficient sepa-
ration techniques, the final yields after multiple purification steps
were invariably small: trace, sub-microgram amounts of EDLF,
definitely insufficient for structural studies.
The low chemical stability of the EDL factors should also
have been considered as possible explanation for the dramati-
cally vanishing EDLF amounts along the purification processes.
But this instability was not investigated in detail. Once a labile
sodium pump inhibitor was signalized in peritoneal dialyzate (44)
with even significantly higher inhibitory potency than ouabain,
but the experiment was not reproduced. Of historical interest is
the mention published 60 years ago by Szent-Györgyi (2) that,
“the cardio-active serum factor if lyophilized and stored, loses its
activity, as it also loses it on repeated freezing and thawing.”
Because of these persistent failures to isolate EDL factors, the
search for endogenous ATPase ligands and assessment of their
putative biological role became increasingly discrepant. Lacking
measurable amounts of the pure EDLF on one side and the
growing body of evidences that toxic CSs of herbal or amphib-
ian origin are unable to function as endogenous ATPase ligands
in mammals became an unsolvable problem. Further controver-
sies were caused by the sugar moieties of the cardiac glycosides
comprising desoxy-sugars (e.g., rhamnose, digitoxose) which were
never identified in mammals, making it unlikely that such desoxy-
glycosides can genuinely exist and act as endogenous ligands in
these animals.
Estimated from their evolutionary history CSs identified in
flowering plants could not be older than 100 million years and
steroids from amphibians must be “younger” than 400 million
years. It is very unlikely that such compounds have existed as reg-
ulatory ligands of the ATPase pumps 3500 million years ago in the
prokaryote membrane.
After the successful evolution of the archaic ATPase 3.5 bil-
lion years ago, it was no more evolutionary pressure to improve
this perfectly working ion-pumping mechanism or to change its
endogenous regulatory ligand. The adaptation on the growing
complexity of multicellular organisms was accomplished by diver-
sification of the subunits or by the combination of substructures,
without essential changes of the basic pumping mechanism.
Finally, it should be remarked that the search for identifica-
tion of the EDL factors had considered almost exclusively organic
candidates (38). This was not fully justified as the essential chem-
ical reaction of the pumping cycle is the binding (and release)
of a simple inorganic phosphate group. The lack of specific 3D
structures in solution makes simple inorganic salts rather unable
to fit a receptor site and to work as endogenous ligands contrary
to organic substances. However, some inorganic poly-oxo-acids
derived from metalloids such as Be, Al, Si, Ge, As, V, Cr, or Mn are
able to form 3D structures in solution to fit into a receptor site.
Actually the predominant part of these poly-oxo-acids and their
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salts are toxic for living organisms, which reduces the number of
candidate endogenous ligands.
Several criteria of the putative EDLFs have been formulated
previously, among others by Goto et al. (38). Completing the ear-
lier list with a few criteria, we consider that the endogenous ATPase
ligands should have characteristics as:
a. inhibitor of the Na+/K+-ATPase,
b. inhibitor of other P-type ATPases,
c. ubiquitously distributed,
d. bioavailable and eliminable,
e. non-toxic for animals,
f. was present in a very early stage of the evolution,
g. sensitive to drying and freeze-drying,
h. specific 3D structure in solution.
These properties can also explain the difficulties met earlier in
the isolation and characterization of pure EDLFs. Further efforts
are needed to disclose the detailed mechanism of action at cellular
and physiological level of the actual EDL factors.
ATPase INHIBITORY VANADATES
The inhibition of the Na+/K+-ATPase by vanadate was discov-
ered in year 1977 with the accidental observation (45, 46) that the
reagent grade ATP of Sigma was contaminated with an ATPase
inhibitory substance, identified as sodium vanadate (Na3VO4).
The similar (isoelectronic) structure of the vanadate and phos-
phate ions was considered as a probable mechanism of the inhibi-
tion by vanadate in competition to the phosphate binding site.
Investigating the interaction of vanadates (47) with fluorescein-
labeled SERCA, it was observed that vanadate impeded the high-
affinity Ca2+ binding to the enzyme at 4°C. Vanadate inhibits
the phosphorylation reaction by inorganic phosphate but had no
effect on the phosphorylation by ATP. It was suggested that vana-
date binds to the low-affinity ATP binding site of the ATPases,
which is exposed only in the E2 conformation of the enzyme.
Interactions between SERCA and vanadate ions in solution
have been investigated by 51V-NMR spectra indicating that mono-
and oligo-vanadates are bound to SR membrane influencing the
structure of Ca2+-ATPase (48). Actually, the mono and oligo-
vanadate species form some complex equilibria impeding the
establishment of rigorous structure–activity correlations.
In the presence of Ca2+, it was observed that tetra- and deca-
vanadate [V10O28]6- binds to the SERCA pump, whereas mono-
meric vanadate binds to the SR only when ATP is present. There are
further arguments that decavanadate clearly differs from mono-
or small-vanadate oligomers in preventing the accumulation of
Ca2+ ions by SR vesicles, which is coupled to ATP hydrolysis (49).
Biological studies with vanadium often disregarded the for-
mation of decameric vanadate species known to manifest high-
affinity interaction with many proteins such as myosin and the SR
calcium pump (50). Vanadium is accumulated in mitochondria
in particular when decavanadate is administered. These findings
point out the contributions of decavanadate to in vivo effects
induced by vanadium in biological systems.
An increasing volume of data suggests the putative biological
importance of decavanadate, a vanadate oligomer that eventually
occurs in the cytoplasm more often than expected (51). Specific
interactions of decavanadate have been clearly demonstrated for
Ca2+-ATPase, myosin, and actin, considered as major proteins
in muscle contraction and its regulation. Based on crystal struc-
ture data, the binding of the SERCA inhibitory decavanadate was
localized (19, 52) to the ATP binding site between the cytoplasmic
domains A, N, and P of the thapsigargin-inhibited enzyme in the
absence of Ca2+ as shown by Figure 1B of the present paper.
Vanadate compounds show a significant antidiabetic efficacy.
Sodium vanadate was applied in diabetes therapy 22 years before
the first use of insulin to treat diabetes in human beings (53,
54). Besides its insulin-mimetic action, vanadate inhibits the
glucose-6-phosphatase (G6P) enzyme, with a key role in glucose
metabolism.
The proposal of Kramer et al. (55) to consider vanadium di-
ascorbate with a molar mass of 403 Da as a candidate EDLF is
worth mentioning. However, this hypothesis has not been con-
firmed since vanadate ions are not ubiquitously distributed in
mammals and are toxic in particular by accumulation in some
organs.
ATPase INHIBITORY MCS-FACTORS
Our way to disclose the structure of the assumed EDLFs is a typ-
ical example of serendipity. At the end of 1990s, we investigated
at the Max-Planck Institute for Biochemistry in Munich an herbal
product isolated from the roots of Helleborus species. The plant
product contained, besides other components, the cardiac glyco-
side hellebrin with strong NKA-inhibitory potency. The chemical
stability of hellebrin was monitored by measuring the inhibition
of Na+/K+-ATPase, starting therewith a very intensive and prolific
collaboration with Hans-Jürgen Apell and Robert Stimac from the
University of Konstanz (GER), which led finally to the disclosure
of the novel ATPase-inhibitory factor.
The alkaline treatment destroyed hellebrin and annihilated the
NKA-inhibitory effect but, as the alkaline boiling was accidentally
prolonged for several hours, a very potent novel NKA inhibitor was
generated (56). By the HPLC on RP-18 column, the pure inhibitory
compound eluted closely after the injection peak, or delayed if it
was attached to some lipophilic components. Similar characteris-
tics have been reported by the HPLC analysis of the earlier EDLF
preparations from biological samples (38–43).
The main component of the plant material subjected to alka-
line boiling was a resin-like compound, similar to the poly-
meric carbon suboxide (57). Therefore, it was thought that the
obtained potent ATPase inhibitor could be a low molecular weight
decomposition product of this polymer. For the structure of the
de-polymerization product, we assumed a repeatedly condensed
4-pyrone frame that forms a supplementary cage-type macro-
cycle with formula (C3O2)n where (n= 4, 6, or 8). We named
the inhibitor MCS, macrocyclic carbon suboxide (56). Tentatively,
this MCS was suggested as probable EDLF and natriuretic factor
(58).
MCS factors showed a rigorously reproducible potent inhibi-
tion of the Na+/K+-ATPase, Ca2+-ATPase, H+/K+-ATPase, and
K-dp-ATPase with IC50 values in the 0.2–0.5µg/mL range. The
mechanism of Na+/K+-ATPase inhibition by the MCS factor was
investigated with the fluorescent styryl dye RH421, a dye known to
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reflect changes of local electric fields in the membrane dielectric. It
was found that the binding of the MCS to the Na+/K+-ATPase is
not competitive with ouabain (59, 60). MCS factors interact with
the Na+/K+-ATPase in the E1 conformation of the ion pump
and induce a structural rearrangement that causes a change of
the equilibrium dissociation constant for one of the first 2 intra-
cellular cation binding sites. The MCS-inhibited state was found
to have bound one cation (H+, Na+, or K+) in one of two non
Na+ specific binding sites, and the other Na+ ion was bound at
high Na+ concentrations to the highly Na+-selective ion-binding
site (60).
The proposal with cage-form condensed macrocyclic carbon
suboxide structure was apparently supported by the mass ion peaks
(m/z) containing multiples of the 68.03 Da unit, the molar mass
of the C3O2.
The main m/z peaks in ESI-MS spectra (Figure 2) have been
assessed as small multiples of the carbon suboxide unit (68 Da)
with 1 Na+ ion according to the formula [(C3O2)n·Na]+ thus,
m/z= 159 Da correspond ton= 2; 295 Da (n= 4); 431 Da (n= 6),
and 567 Da (n= 8). The small MH+ peaks at 275, 409.2, and
544.2 Da were also perceptible in the mass spectrum (56).
Interestingly, a molar mass ion at M= 408 Da (MH+= 409;
MNa+= 431 Da) was identified in some earlier EDLF prepara-
tions from biological sources, e.g., human plasma (61), placenta
(62), or bound to a hypertension-associated plasma protein (63).
It can be speculated about the possible identity of these factors
and our MCS product but only the same molar mass ion value is
not sufficient to prove or disprove this identity. The fine structure
of the mass spectra may also differ due to the different ionization
techniques, i.e., FAB used by Weiler et al. (63) and ESI-MS applied
by us (56).
Although the ATPase-inhibitory effect of the MCS factors on
several P-type ATPases and the mechanism of action on NKA were
rigorously reproducible, the structure with head-to-tail condensed
pyran-4-one rings supplementary bond in a cage-like macro-cycle
could not be confirmed by synthesis despite huge experimental
efforts with Frank Freudenmann and Luis Moroder at the MPI for
biochemistry in Munich.
FIGURE 2 | ESI-mass spectrum of the NKA-inhibitory MCS factor
corresponding to some mass ion fragments resulted by
decomposition of SOSA.
Likewise not confirmed were the specific 13C-NMR signals and
the UV-absorbance peaks expected for the macrocyclic condensed
pyran-4-one structure. The assessment of the mass spectrum as
multiples of a 68 Da unit was correct but the attribution of this
mass to C3O2 was erroneous. These disagreements required the
revision of the proposed macrocyclic cage-structure.
SPHERICAL OLIGO-SILICIC ACID (SOSA)
The decisive hint to disclose the actual chemical structure of our
NKA-inhibitory factor came from revision of the blind probe of
the described alkaline preparation. Surprisingly, the several hours
boiling of the NaOH solution alone, without any other reagent
yielded a similarly potent ATPase inhibitor as that obtained by
alkaline boiling of the plant polymer.
The mystery was explained by identifying small amounts of
sodium silicate in the solution leached from the glass flask by
its prolonged alkaline heating in oil bath at 120°C. Applying the
proper neutralization-activation procedure (56), this silicate was
transformed to the highly active ATPase-inhibitory factor iden-
tified as spherical oligomers of silicic acid. The generation of
biologically active oligomeric condensation products from the
inactive monosilicic acid was totally unexpected and thus very
surprising.
We considered that this finding could have implications in
clearing of some controversial disputes within the following
research areas:
Regarding the biological role of silicon, it was generally agreed
that Si provides structural support in plants and is beneficial of
bones and elasticity of cartilages in animals. But neither a Si con-
taining biologically active substance, nor a protein, which needs
Si has been found in animals. Identifying the SOSA as biologi-
cally active water-soluble Si compound (64), a decisive argument
has been provided in support of the assumed biological role
(essentiality) of this element.
The assumed existence of EDLFs and their putative identity
with cardiac glycosides was the subject of debates for several
decades. The proposed identity of EDLF (65) with the SOSA was
a novel approach suggesting the reconsideration of the divergent
opinions.
The structure of the ATPase-inhibitory SOSA is formed by
successive condensation of a few (oligos in Greek) molecules of
monosilicic acid H4SiO4 according to the equation (Eq. 1) where






mono-silicic acid oligo-silicic acid
x = 1.5 → [SiO1.5 (OH)]n
SOSA
(1)
The value x = 1.5 in the general formula [SiOx(OH)4-2x]n is
congruent with a particular symmetry of the multi-cyclic sili-
cic acid oligomers corresponding to polyhedral symmetry, i.e,
prismatic hexamer (n= 6), cubic octamer (n= 8), and prismatic
decamer (n= 10) structure, known as silsesquioxanes with general
formula [SiO1.5OH]n and shown by Figure 3.
The spherical form of the oligo-silicic acid SOSA is accom-
plished for x = 1.5 in the general formula [SiOx(OH)4-2x]n and
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FIGURE 3 | Structure of polyhedral silsesquioxanes.
is assumed as the natural continuation of the polyhedral series
with formula [SiO1.5(OH)]n for values of n> 20. There is an
interesting formal resemblance with the series of Platonic bodies
(tetrahedron, cube,. . .sphere) from geometry.
Actually, the cage-type condensed polyhedral silsesquioxanes
have all Si-OH groups at the external vertices with nearly axial ori-
entation. A similarly external distribution of the Si-OH groups is
accomplished by the here disclosed nearly spherical oligomers of
the silicic acid. SOSA molecules as next term in the series of poly-
hedral structures with the same general formula [SiO1.5(OH)]n
have the same ratio between the Si: O: H atom= 1: 2.5: 1.
But, there are significant differences between the chemical
structure and properties of the polyhedral and of the spherical
silica. The predominant difference is that polyhedral silsesquiox-
anes inhibit neither Na+/K+-ATPase nor other ATPases conversely
to the strong ATPase-inhibitory SOSA. Structurally, all polyhedral
silsesquioxanes (Figure 3) comprise only Q3 type Si atoms, i.e.,
each one is involved in three (Si)-O-Si bonds and one (Si)-OH
bond.
The spherical shape of the oligo-condensed silicic acid with
x = 1.5 is accomplished by some preferred “n” values. Figure 4
shows the SOSA molecule with n= 36, as ball and stick model.
This SOSA molecule with formula [Si36O54 (OH)36] comprises in
its internal shells 4+ 8= 12 Si atoms of type Q4 (without Si-OH
bonds). In the external shell, there are 12 Si atoms of type Q3 (with
one Si-OH bond) and 12 Si atoms of type Q2 (with two Si-OH
bonds). It is observed that the 36 external Si-OH bonds are dis-
played on the external surface strongly facilitating the hydrophilic
interactions with proteins.
Applying the gel-permeation chromatography (GPC) method,
molar mass values in the range of 1.2–6.0 kDa have been obtained
of the spherical condensed silicic acid oligomers. For the SOSA
molecule illustrated on Figure 4 there resulted M = 3.2 kDa, cor-
responding to molecular diameter φ= 2.2 nm further confirmed
by dynamic light scattering (DLS).
The mass ion peaks of SOSA obtained by ESI-MS technique
were practically the same as those identified in the spectrum of
our MCS factor (Figure 2). Actually these m/z peaks correspond
to small ionic fragments resulted by the split of the large SOSA
molecules in the ionization chamber. The main mass ion peaks
FIGURE 4 | Structure of SOSA with formula: [Si36O54 (OH)36] with 36
Si-OH bonds on the external surface of the spherical molecule.
correspond to the formula [(Si2O5)q·Na]+ with m/z= 159 Da for
q= 1; 295 Da for q= 2; 431 Da for q= 3, and 567 Da for q= 4.
Similar mass spectra have been observed by decomposition of
condensed silsesquioxanes (66, 67).
In fact, the erroneous assessment of the mass ion peaks as
derived from carbon suboxide was caused by the accidental iden-
tity of the molar mass of C3O2 M= 68.03 Da and the mass of
the 1/2 Si2O5 (di-silicate) ion with M= 68.08 Da, resulted by
the decomposition of SOSA. In conclusion, the mass ion peaks
on Figure 2 correspond rather to the formula [(Si2O5)q·Na]+
of SOSA and not to the formula [(C3O2)n·Na]+ as initially
suggested.
SOSA AS POSSIBLE ENDOGENOUS FACTOR
With the confirmed potent inhibition of several P-type ATPases,
SOSA fulfills the main condition as a candidate ATPase lig-
and. Its classification as an endogenous factor requires further
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that SOSA should be produced within the organism, tissue,
or cell. This condition is satisfied with the presumed biosyn-
thetic pathway of SOSA by spherical oligomerization of the
monosilicic acid (H4SiO4) ubiquitously distributed in plants and
animals (68, 69).
A human body contains approximately 1 g of Si in various com-
binations with oxygen (generic name: silica). Almost all silica in
the body is bound to biomolecules and tissues and only a minor
part circulates as dissolved silicic acid in blood plasma and urine
(70). The plasma level of silicic acid is 0.7 mg/L corresponding to
0.2 mg/L silicon. Infants have two- to three-fold higher Si plasma
level, but in contrast aged persons and pregnant women have sig-
nificantly lower values of Si. For human beings, the daily ingested
amount of Si is estimated to be 30–50 mg and the same amount
is eliminated in urine. After meals, the plasma concentration of Si
increases 30–50%, and returns after a few hours to the initial level
(71). The regulatory mechanisms of Silicon homeostasis require
elucidation.
The catalytic action of a biomolecule to accomplish the spher-
ical oligomerization of silicic acid yielding SOSA is presumed.
Proteins catalyzing high-grade polymerization of silicic acid have
been found (67) in algae (silaffin) or sponges (silicatein). Biomol-
ecules favoring the spherical oligomerization of silicic acid have
not yet been identified.
The mechanism of ATPase regulation by the probable endoge-
nous ligand SOSA is not fully understood. According to the
unusual physical–chemical properties of SOSA and to its specific
interactions with the Na+, K+, H+, Mg2+, or Ca2+ ions and with
the ATPase protein, some challenging proposals for the regulation
mechanism may be formulated.
ASSUMED REGULATORY MECHANISM OF SOSA
Transmembrane ion pumping may be physically influenced by
SOSA located in a receptor cavity along the ion-transport pathway
of the ATPase molecule. The SOSA molecule should behave like a
multi-anionic gel with selective binding or permeability effects on
cationic species depending on their concentration, charge and size.
The interaction of SOSA with the ATPase protein is assumed
on the cytoplasmic site of the ATPases in the E1 conformation
as revealed by charge transfer investigations with the dye RH421
(60). According to these data, SOSA should inhibit the X1E1 state,
manifesting complex interactions with different X ions (Na+, K+,
or H+) and with Na+ ions in the (Na)NaE1 state. Structural
details of the very complex binding of the sodium ions to the
NKA in the state preceding phosphorylation have been disclosed
by high-resolution crystal structure (72).
The ion-sensitive nature of our ATPase inhibitory factors MCS
(disclosed as SOSA) was remarked in Ref. (60) assuming that the
concentration of the Na+ and of other ions may cause significant
structural rearrangements. The in vitro ion-sensitive structure of
SOSA is also supported by DLS measurements. Tentatively, it could
be assumed that the SOSA structure at [Na+]< 5mM inhibits the
sodium pump but the structure at [Na+]≥ 5 mM should acti-
vate it. A possible activation mechanism could be by favoring
the differentiate binding of Na+ ions to the E1 conformation
and promoting the phosphorylation step. Accepting this hypoth-
esis, the generally found cytosolic level of [Na+]= 5.0 mM in the
eukaryotic cells could be a consequence of the structural change of
the archaic ligand SOSA, which happens accidentally at this Na+
ion concentration.
The here proposed probably archaic regulatory mechanism
of the NKA pump by ion-dependent structural changes of the
endogenous ligand could also work for other ATPases. The ion
concentration threshold for the activation of other ATPases should
depend upon the concentration of the ions to be pumped and their
interaction with SOSA. This regulatory mechanism, assuming the
ion-sensitive structural variation of the archaic ligand SOSA, can
explain the astonishing manifoldness of the same well-conserved
ion-pumping mechanism in the hitherto identified more than 200
different P-type ATPase pumps.
CONCLUSIONS AND OUTLOOK
With almost all Si-OH bonds disposed on the external surface
of SOSA, this substance should bind preferentially to hydrophilic
domains of the target proteins. In P-type ATPases, the well-
conserved phosphorylation site between the cytoplasmic domains
P and N provides an adequate binding site for SOSA molecules
similar to decavanadate (Figure 1).
Although SOSA inhibits NKA at sub-micro-molar concentra-
tion, its direct competition with ouabain for the hydrophobic
steroid binding site in NKA is less probable. The non-competitive
binding mechanism of our hydrophilic ATPase inhibitor and
ouabain was confirmed by the fluorescence dye measurements
of Stimac et al. (59, 60). An apparent competition may appear
if the NKA conformation required for SOSA binding and that
required for ouabain binding are different (C. Toyoshima, personal
communication).
The ion-concentration dependent structural changes of SOSA
suggest a probable archaic regulation mechanism of the sodium
pump and of other ATPases where the pump ligand is sensing the
nature and molarity of the ions to be pumped. It is a challeng-
ing idea that the transmembrane ion pumping with fundamental
importance for many essential life processes should be regulated
by the cation-sensitive structure of an inorganic acid.
The identified chemical properties and enzymatic activities
of SOSA are congruent with the predicted characteristics of the
EDLFs of the P-type ATPases. Table 1 shows a synoptic pre-
sentation of the assumed characteristics of the putative EDLF
factors in comparison with that of candidate substances: ouabain,
marinobufagenin, vanadate, and the here disclosed SOSA.
Summarizing the characteristics of the SOSA, it may be con-
cluded that these match the predicted criteria of the endogenous
ligands of the NKA and probably of further P-type ATPases:
a. SOSA inhibits with similar potencies (IC50 ~ 0.2–0.5µg/mL)
the ouabain-sensitive Na+/K+-ATPase from rabbit medulla
and the ouabain-insensitive enzyme from rat.
b. SOSA inhibits Ca2+-ATPase from SR, H+/K+-ATPase from
gastric membrane and of K-dp-ATPase from Escherichia coli
with IC50 values in the range of 0.2–0.5µg/mL.
c. There are no sensitive methods to differentiate between
mono and oligo-silicic acids in cells. But the assay of the
NKA-inhibitory factors EDLF in urine and plasma suggest the
probable presence of SOSA in these biological fluids.
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Table 1 | Comparison of the endogenous ATPase ligand candidates.
EDLF Ouabain Marino-bufagin Vanadate SOSA
Characteristics
C-1 Chemical nature ND Cardiac glycoside Bufadienolide steroid Inorganic, poly-oxo-acid Inorganic poly-oxo-acid
C-2 Molar mass (kDa) 0.4–5.0 0.58 0.4 0.12–1.5 1.4–6.0
C-3 Stability by drying Low Stable Stable Limited Low
C-4 Structural stability ND Stable Stable pH sensitive equilibra Cation and pH sensitive
C-5 Nature to ATPase binding site ND Hydrophobic Hydrophobic Hydrophilic Hydrophilic
C-6 Distribution Ubiquitous Only in a few plant Predominantly in Limited Ubiquitous
species amphibians
C-7 Mammalian occurrence Yes No No Only in traces Ubiquitous
C-8 Evolutionary age million years Myr >3500 Myr <60 Myr <360 Myr >3500 Myr >3500 Myr
Biochemistry
B-1 Toxicity Low High High Moderate Low
B-2 Biosynthesis Predicted Only in a few plant Predominantly in Improbable From monosilicic-acid
species amphibians
B-3 Na,K-ATPase Inhibitor Inhibitor Inhibitor Inhibitor Inhibitor
B-4 SERCA Inhibitor No No Inhibitor Inhibitor
B-5 H/K-ATPase Inhibitor No No Inhibitor Inhibitor
B-6 K-db-ATPase Inhibitor No No Inhibitor Inhibitor
ND: not determined.
d. Monosilicic acid is present in almost all cells; thus, its adequate
transformation into SOSA can occur in situ, catalyzed and/or
controlled by proteins.
e. Preliminary data revealed a reduced toxicity by per-oral and a
moderate toxicity by intravenous or intramuscular administra-
tion of SOSA. Renal elimination is assumed.
f. There are no reasons to doubt the presence of silicic acid and
of SOSA in the early history of the evolution.
g. SOSA is stable in solution for several years but it loses its activ-
ity by freeze-drying probably through the forced intermolecular
condensation of water molecules.
It is planned to obtain further structural details of the interac-
tion of SOSA with ATPase proteins with possible implication for
the regulation of the pump. One of the very intriguing questions
is to investigate the influence of the concentration of Na+, K+,
Mg2+,Ca2+, and other ions on the structure of SOSA. The fur-
ther great challenge for ongoing research is to establish the role of
SOSA in ATPase related cellular and physiological processes and
to explore its possible health-care applications in some connected
pathologies (73, 74).
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